Company
Kura
Last checked: Nov 21, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
1
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 110
Recent approvals
Originals and efficacy supplements, newest first.
- Komzifti approved NovelBreakthrough therapyPriority reviewOrphanNov 13, 2025
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLPivotal-lookingRecruiting
Kura Oncology, Inc.Industry
NCT07007312 · 1,300 participants (planned) · Start Sep 26, 2025 · Primary completion Nov 2031
Drug: Ziftomenib; Placebo and 4 more · For: Acute Myeloid Leukemia (AML)
Sites: Gilbert, Arizona; Clovis, California; La Jolla, California · 141 sites in all
Marketed drugs (1)
Newest FDA action first.
- Komzifti Ziftomenib · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.